KALA - Kala Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
10.91
+0.16 (+1.49%)
As of 3:00PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close10.75
Open10.71
Bid10.95 x 1000
Ask10.99 x 1300
Day's Range10.71 - 11.01
52 Week Range10.34 - 24.46
Volume54,363
Avg. Volume224,772
Market Cap268.302M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-2.55
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.00
Trade prices are not sourced from all markets
  • Business Wire3 days ago

    Kala Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Kala Pharmaceuticals, Inc. (KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 69,500 shares of Kala Pharmaceuticals common stock to seven new employees.

  • TheStreet.com14 days ago

    Six Biotechnology Names on My Watch List

    The indices have been slowly drifting lower after a gap up open. Early breadth was around 3 to 1 positive but its now down to around 4-3 positive. The bulls are not producing much positive momentum but the bears are doing an even worse job of producing negative momentum.

  • GlobeNewswire24 days ago

    Research Report Identifies Holly Energy Partners, First Merchants, Enbridge Energy Management, Activision Blizzard, Coherus BioSciences, and Kala Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Aug. 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Holly ...

  • Business Wire26 days ago

    Kala Pharmaceuticals to Present at Upcoming Investor Conferences

    Kala Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating parti

  • Biotech Stock Roundup: GILD Gets EC Nod for Yescarta, AMGN Submits Kyprolis sNDA
    Zacks26 days ago

    Biotech Stock Roundup: GILD Gets EC Nod for Yescarta, AMGN Submits Kyprolis sNDA

    Regulatory and pipeline updates comprise some of the key developments in the biotech sector this week. These include Gilead's Yescarta approval in Europe.

  • Reuterslast month

    U.S. FDA approves Kala Pharma's eye pain drug

    The U.S. Food and Drug Administration on Thursday approved Kala Pharmaceuticals Inc's treatment for reducing inflammation and pain following an eye surgery. The company said it expects to launch the drug, Inveltys, in the beginning of 2019, with Wedbush Securities estimating peak sales of about $271 million in 2027. The drug was found to have no serious side effects during clinical trials, Kala said.

  • MarketWatchlast month

    Kala stock declines 6% after FDA approves ocular surgery product

    Kala Pharmaceuticals Inc. (KALA) shares dropped 6% in Thursday afternoon trade after the Food and Drug Administration approved its corticosteroid for inflammation and pain after eye surgery. Having to dose a product four times a day "can be burdensome for patients as they are taking multiple eye drop products following surgery and is believed to reduce patient compliance," the company said. Kala plans a launch for early 2019, and said it will hire a specialty sales force to cater to U.S. eye care professionals.

  • H.C. Wainwright Maintains Buy on Kala Pharmaceuticals (KALA) Ahead of Upcoming PDUFA Date
    SmarterAnalystlast month

    H.C. Wainwright Maintains Buy on Kala Pharmaceuticals (KALA) Ahead of Upcoming PDUFA Date

    H.C. Wainwright analyst Ram Selvaraju is out this morning with another bullish note on shares of Kala Pharmaceuticals (NASDAQ:KALA), reiterating a Buy rating and price target of $35, which represents a potential upside of 197% from where the stock is currently trading. Selvaraju continues to see a favorable risk/reward profile on Kala heading into the August 24 PDUFA date for lead candidate, INVELTYS. If approved, INVELTYS would be the first FDA-approved corticosteroid eye drop with a twice daily dosing regimen for the treatment of post-operative ocular inflammation and pain. In our view, the combination of LE’s safety profile and dosing convenience should allow INVELTYS to seize market share from branded eye drops such as Lotemax and Durezol, as well as generic prednisolone.

  • Associated Press2 months ago

    Kala Pharma: 2Q Earnings Snapshot

    The Waltham, Massachusetts-based company said it had a loss of 60 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...

  • Business Wire2 months ago

    Kala Pharmaceuticals Reports Second Quarter 2018 Financial Results

    – PDUFA Target Action Date for INVELTYS™ is August 24, 2018 –

  • Business Wire2 months ago

    Kala Pharmaceuticals to Present at the Wedbush PacGrow Healthcare Conference

    Kala Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle technology, today announced that it will present at the 2018 Wedbush PacGrow Healthcare Conference in New York, NY.

  • Kala Pharmaceuticals (KALA), Durect (DRRX), and Amarin (AMRN) Reiterated with a Buy at H.C. Wainwright
    SmarterAnalyst2 months ago

    Kala Pharmaceuticals (KALA), Durect (DRRX), and Amarin (AMRN) Reiterated with a Buy at H.C. Wainwright

    In a research note issued Wednesday, H.C. Wainwright analyst Ram Selvaraju reiterated coverage on shares of Kala Pharmaceuticals (NASDAQ:KALA), with a Buy rating and price target of $35, which represents a potential upside of 173% from where the stock is currently trading. The reiteration follows the news that the company's third phase 3 trial (STRIDE 3) of KPI-121 0.25% for the treatment of dry eye disease (DED), had dosed its first patient. Selvaraju wrote, "The STRIDE 3 trial design has specific modifications to the inclusion/exclusion criteria to address key factors that could improve the probability of success, according to management.

  • Business Wire2 months ago

    Kala Pharmaceuticals Announces Dosing of First Patient in Phase 3 STRIDE 3 Trial of KPI-121 0.25% in Patients with Dry Eye Disease

    Kala Pharmaceuticals, Inc. (KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, today announced that the first patient has been dosed in STRIDE 3 (Short Term Relief In Dry Eye), its Phase 3 trial of KPI-121 0.25% for the short-term treatment of dry eye disease. If approved, KPI-121 0.25% could be the first FDA-approved product for the short-term treatment of dry eye disease,” said Kim Brazzell, Chief Medical Officer. “The STRIDE 3 trial design reflects specific modifications to the inclusion/exclusion criteria of our previous trials to address key factors which we believe will improve the probability of success.

  • GlobeNewswire2 months ago

    Recent Analysis Shows Kala Pharmaceuticals, Integer, Carnival, Coty, Sykes Enterprises, and Agilent Technologies Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, July 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Kala ...

  • According to H.C. Wainwright, This Biotech Stock Can Jump to $35
    SmarterAnalyst2 months ago

    According to H.C. Wainwright, This Biotech Stock Can Jump to $35

    It's been tough sledding for Kala Pharmaceuticals (NASDAQ:KALA) shareholders. The company's share price has lost approximately 46% year-to-date due to the fact that its second Phase 3 trial in dry eye disease (DED) did not meet the symptom endpoint. Since this candidate is based on a well-known, validated corticosteroid that has been used for many years in ocular applications, and given the fact that the NDA was filed via the 505(b)(2) regulatory pathway, Selvaraju has high confidence that INVELTYS should be approved by August 24 (the PDUFA date).

  • Kala Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
    Zacks2 months ago

    Kala Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

    Kala Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

  • Options Traders Expect Huge Moves in Kala Pharmaceuticals (KALA) Stock
    Zacks3 months ago

    Options Traders Expect Huge Moves in Kala Pharmaceuticals (KALA) Stock

    Investors in Kala Pharmaceuticals (KALA) need to pay close attention to the stock based on moves in the options market lately.

  • Wedbush Sees 240% Upside for Kala Pharmaceuticals (KALA) Stock; Here’s Why
    SmarterAnalyst3 months ago

    Wedbush Sees 240% Upside for Kala Pharmaceuticals (KALA) Stock; Here’s Why

    Wedbush analyst Liana Moussatos is out today with a bullish note on shares of Kala Pharmaceuticals (NASDAQ:KALA), following the drug maker's announcement that it plans to submit a New Drug Application (NDA) to the FDA for its dry eye treatment KPI-121 0.25% during the second half of 2018, while initiating an additional Phase 3 trial (STRIDE 3) in the third-quarter of this year, as per FDA suggestion.

  • Business Wire3 months ago

    Kala Pharmaceuticals Announces Update to KPI-121 0.25% Development Plan

    Kala Pharmaceuticals, Inc. (KALA), today provided an update on the development plan for KPI-121 0.25%, which if approved could be the first FDA-approved product for the short-term treatment of dry eye disease. The Company announced that it plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) during the second half of 2018. The NDA will include data from three clinical trials studying approximately 2000 patients, including one Phase 2 trial and two Phase 3 efficacy and safety trials.

  • Associated Press5 months ago

    Kala Pharma: 1Q Earnings Snapshot

    The Waltham, Massachusetts-based company said it had a loss of 46 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • Business Wire5 months ago

    Kala Pharmaceuticals Reports First Quarter 2018 Financial Results

    Kala Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle technology with an initial focus on the treatment of eye diseases, today reported financial results for the quarter ended March 31, 2018.

  • Business Wire5 months ago

    Kala Pharmaceuticals Strengthens Commercial Organization in Preparation for First Product Launch

    Kala Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating

  • Business Wire5 months ago

    Kala Pharmaceuticals to Present at Upcoming Investor Conferences

    Kala Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle technology, today announced that Mark Iwicki, Chairman and Chief Executive Officer, will provide a corporate overview at the Bank of America Merrill Lynch 2018 Health Care Conference and the Jefferies 2018 Global Healthcare ...

  • ACCESSWIRE5 months ago

    Wired News – Capricor’s New Pre-Clinical Study Establishes that Repeated Doses of CAP-1002 Lead to Enhanced Exercise Capacity in a Disease Model of Duchenne Muscular Dystrophy

    LONDON, UK / ACCESSWIRE / April 23, 2018 / Active-Investors.com has just released a free research report on Capricor Therapeutics, Inc. (NASDAQ: CAPR) ("Capricor"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CAPR as the Company's latest news hit the wire. On April 19, 2018, the Company announced that its pre-clinical study has established that repeated dosing of its lead candidate, CAP-1002, yields an increase in exercise performance in a disease model of Duchenne Muscular Dystrophy (DMD), the mdx mouse.